Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. University of California San Francisco, San Francisco, California, United States



Survival: 5.6 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs: Paraplatin
Country: United States
   
City/State/Province: San Francisco, California
   
Hospital: University of California San Francisco
   
Journal: Link
   
Date: 4/2003

Description:
Patients: This Phase II study involved a total of 121 patients with recurrent malignant gliomas. Eighty patients had glioblastoma multiforme and 41 patients had anaplastic glioma.

Treatment: Patients were divided into two treatment groups. Patients in Group A received two drugs – RMP-7 (bradykinin analog to open blood brain barrier) and carboplatin (paraplatin). Patients in Group B received only carboplatin (paraplatin) with placebo.

Toxicity: Toxicity was mainly hematological and there were no differences in grade 3 or grade 4 hematologic toxicity between the groups (those that received RMP-7 with carboplatin and those that only received carboplatin). Compared to placebo patients however, those patients who received RMP-7 (Group A) had a higher number of the following adverse events: vasodilation, nausea, headache, astehenia, abdominal pain, tachycardia, and back pain.

Results: Median survival for the glioblastoma multiforme patients who received RMP-7 with carboplatin was 24.0 weeks (5.6 months). The authors concluded, “In summary, carboplatin in combination with RMP-7 in the doses and schedules used in this trial was not successful in patients with recurrent malignant glioma.”

Correspondence: M. Prados, MD

Support: The biotechnology company, Alkermes is involved in developing and commercializing RMP-7. The study was supported in part by Alkermes and two of the study authors have a financial interest in RMP-7.

E-mail to a Friend Email Physician More Information